ovarian cancer

ASCO20 Virtual Scientific Program: #ASCO20
May 13, 2020
Leslie Fannon Zhang, ASCO staff

ASCO20 Virtual Scientific Program: Effect of Quitting Smoking on Lung Cancer Survival, Maintenance Therapy for Recurrent Ovarian Cancer, Geriatric Assessments, Medicaid Expansion and Overall Cancer Mortality, and Videoconferencing for Caregivers

English
Leslie.Fannon.Zhang

Read early research highlights just released from the ASCO20 Virtual Scientific Program. They include studies on quitting smoking and lung cancer survival, recurrent ovarian cancer treatment, geriatric assessment for patients receiving systemic therapy, how Medicaid expansion is impacting U.S. cancer mortality, and using videoconferencing with long-distance caregivers.

Read More >>
ASCO20 Virtual Scientific Program: #ASCO20
May 13, 2020
Leslie Fannon Zhang, ASCO staff

Programa científico virtual ASCO20: Efecto de dejar de fumar en la supervivencia, un tratamiento para el cáncer de ovario recurrente, evaluaciones geriátricas, expansión de Medicaid y mortalidad por cáncer, y videoconferencia para cuidadores

Spanish
Leslie.Fannon.Zhang

Lea los puntos destacados iniciales de la investigación del programa científico virtual ASCO20 que se acaban de publicar. Estos incluyen estudios sobre dejar de fumar y la supervivencia al cáncer de pulmón, el tratamiento del cáncer de ovario recurrente, la evaluación geriátrica para los pacientes que están recibiendo terapia sistémica, cómo la ampliación de Medicaid afecta a la mortalidad por cáncer en EE. UU. y el uso de videoconferencias con los cuidadores a distancia.

Read More >>
2019 ASCO ® Annual Meeting; #ASCO19
June 2, 2019
Monika Sharda, ASCO staff

ASCO Annual Meeting 2019: Treatment Advances for Metastatic Prostate Cancer and Pancreatic Cancer, Multiple Myeloma Survival Factors, and Effects of the Affordable Care Act on Cancer Care

English
Monika.Sharda

The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include an effective medication for metastatic prostate cancer, targeted therapy that slows the growth of metastatic pancreatic cancer, how socioeconomic factors may affect survival for multiple myeloma, and how the ACA resulted in earlier treatment and improved equality in care.

Read More >>
May 10, 2019
Claire Smith, ASCO staff

ASCO in the Community: “It Was in the Family”

English
claire.smith

Kimberly Pena was 31 when she was diagnosed with breast cancer, the same age her mother was when she was diagnosed more than 3 decades earlier. She shares her experience with cancer, treatment, and trying to convince her family to be tested for the BRCA genetic mutation.

Read More >>
Meg Gaines; Voices on Cancer
July 19, 2018
Monika Sharda, ASCO staff

An Advocate's Perspective on Patient-Centered Care

English
Monika.Sharda
In this Voices on Cancer podcast interview, ovarian cancer survivor Meg Gaines shares her thoughts on becoming a successful advocate and the importance of involving patients in the health care conversation.
Read More >>
2017 Clinical Cancer Advances
February 1, 2017
Greg Guthrie, ASCO staff

Immunotherapy 2.0: The 2017 Clinical Cancer Advance of the Year

English
gregguthrie

The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively.

Read More >>

Pages

Subscribe to RSS - ovarian cancer